

Form record received

International Workshop on Waldenstrom's Macroglobulinemia <pattersonkent@outlook.com>

Mon 7/15/2024 9:36 AM

To:Patterson, Christopher <Christopher_Patterson@DFCI.HARVARD.EDU>

External Email - Use Caution

Record saved to database with ID: 126

Form ID: 1

Form title: Abstract Submission

Form name: Abstract_Submission

Submitted at: 2024-07-15 09:35:35

Submitter IP: 170.85.71.109

User-ID: 0

Username: -

User full name: -

Submitter provider: Unknown

Submitter browser: Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko)

Chrome/126.0.0.0 Safari/537.36

Submitter operating system: win

First Name: David

Last Name: Tucker

Email: David.tucker1@nhs.net

Registration Type: Delegate

Abstract Title: Improving the Quality of Active Monitoring in Waldenström Macroglobulinemia: Results of a UK-Wide Patient-Centered Experience Survey and Proposed Standard of Care for Active Monitoring From a UK-Wide Patient-Expert Collaboration

Select abstract file to attach:

/home/dkwolfpk2016/public_html/waldenstromsworkshop/media/breezingforms/uploads/tuckeriwmm2024aminwabstract.docx

Additional file (optional):

/home/dkwolfpk2016/public_html/waldenstromsworkshop/media/breezingforms/uploads/activemonitoringinwmappendix1.docx

Conference: IWWM12

Improving the Quality of Active Monitoring in Waldenström Macroglobulinemia: Results of a UK-Wide Patient-Centered Experience Survey and Proposed Standard of Care for Active Monitoring From a UK-Wide Patient-Expert Collaboration

Authors: David Tucker, MD,¹ Harriet Scorer, MD,² Jane Nicholson,² Catherine Ogilvie, MD,³ Charlotte Bloodworth,⁴ Alison McKinney,² Nisa Khan, MPharm,⁵ Zoe Kelsall,⁶ Josephine Crowe, MD,⁷ Shirley D'Sa, MD⁸

Affiliations:

¹Royal Cornwall Hospital, Truro, UK

²WMUK, Alderley Edge, UK

³Raigmore Hospital, NHS Highland, Inverness, UK

⁴Cardiff and Vale University Health Board, Cardiff, UK

⁵BeiGene, UK Ltd, London, UK

⁶Royal Stoke University Hospital, Stoke-on-Trent, UK

⁷Royal United Hospital, Bath, UK

⁸UCLH Centre for Waldenstrom and Related Disorders, University College Hospital NHS Foundation Trust, London, UK

Introduction: Patients with Waldenström macroglobulinemia (WM) are often asymptomatic at the point of diagnosis and may remain so for several years. Regular monitoring for clinical changes, known as watch and wait, active surveillance, or active monitoring (AM), is essential. In the UK there are no data on the consistency or quality of patient experience of AM and no standardized approach to the definition and components of AM.

Methods: To understand the views of patients and healthcare professionals (HCPs) on their AM experience, a steering group was convened. The group included people living with WM and HCPs who manage WM, including consultant hematologists and clinical nurse specialists. A patient survey was created to determine the quality and consistency of AM for people living with WM in the UK. This was designed by WMUK, a UK charity and patient organization supporting people living with WM. Members of WMUK completed the survey via email. To define a standard of care for AM, a survey of 40 Likert-scale statements across 6 clinical domains was created and distributed online to HCPs and people living with WM. The survey responses were

used to inform and create a consensus on recommendations on a new standard of care for AM in WM and a checklist to support and inform the patient-HCP discussion during consultations.

Results:

Patient experience of AM: 168 survey responses were analyzed. Age of respondents was recorded in 10-year cohorts from 35 years to 75+ years; most (34%) respondents were in the 66-74 age range. 150 (89%) respondents lived in England, 11 (7%) in Scotland, 3 (2%) in Wales, and 4 (2%) in Northern Ireland. 108 (78%) respondents had been on AM for >2 years at the time of the survey. Thirty-two (22%) did not receive an explanation of AM at diagnosis, and 116 (69%) did not receive any written information about AM; 108 (64%) respondents stated that they were not directed to support services while on active monitoring. 83 (51%) respondents stated they were not given information on symptoms of disease progression for self-monitoring. 105 (63%) respondents stated their experience of AM could have been improved.

HCP/patient consensus on standards in AM: 232 responses were analyzed (189 [81%] people living with WM and 43 [19%] HCPs), with 39/40 statements attaining very strong ($\geq 90\%$) agreement. No statements failed to meet the agreement threshold (75%). From these, 7 recommendations were created defining AM and minimum clinical standards of AM, outlining the role and composition of the multidisciplinary team, and identifying the need for access to educational materials and support from patient organizations. A patient checklist of areas to cover during consultation was also generated.

Conclusions: This study demonstrates that the patient experience of AM across the UK is highly variable, with more than half of participants stating their experience could be improved. The ensuing consensus statement provides a strong foundation for best clinical practice and a template for the communication of information during the AM phase of WM.

Appendix 1. Waldenström Macroglobulinaemia (WM) patient active monitoring (AM) checklist

| | | | | | |
|---------------|--|------------------|--|-------------|--|
| Patient Name: | | Consultant: | | NHS Number: | |
| DOB: | | Contact details: | | GP: | |

Active monitoring is when your healthcare team monitor your WM, rather than treating it right away. You may hear it called 'active surveillance' or 'watch and wait'. For more information, visit wmuk.org.uk.

What will active monitoring consist of?

- I understand how often I will have monitoring appointments with my healthcare team.
- I understand and am satisfied with the format of my future appointments (e.g., face-to-face, telephone, virtual)
- I understand what tests will need to be performed to monitor my condition and how often these will be performed.
- I feel that I have been given enough information about what to expect during the active monitoring phase of my treatment.

My medical condition

- My current symptoms have been discussed during this consultation.
- I understand what new symptoms I may experience and when to contact my healthcare team.
- I understand that WM can affect my immune system and therefore I should take reasonable precautions to avoid infection, including ensuring my vaccinations are up to date.
- I feel that I have been given enough information about my condition at this time.

Additional support during active monitoring

- I have been provided the contact details of my clinical nurse specialist (CNS)
- I understand what support my CNS can offer me during active monitoring.
- I have been informed of other types of healthcare professional support that may be available to me should I require it (e.g., dietician, physiotherapist, etc.)
- I have been given information about how to contact or access information from patient support groups/charities such as WMUK.

Contributing to further WM research

- My doctor has discussed my enrolment and inclusion of my data in the Rory Morrison Registry with me

My lifestyle

- I understand the impact of my general wellbeing on my condition and the importance of keeping as well as I can.
- I have discussed the importance of regular and appropriate exercise as it relates to my general wellbeing and my condition with my WM care team.
- I have discussed with my WM care team, the importance of ensuring any other medical issues I may have are being addressed and managed well by my GP or other healthcare provider.

If you are unable to tick any of the boxes above, please discuss your concerns or questions with you CNS or key worker

Notes